Drug Trial Radar · NCT06764615
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
May 28, 2025
Primary completion
Dec 30, 2029
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension of the parent studies, TAK-279-CD-2001 (NCT06233461), TAK-279-UC-2001 (NCT06254950) and TAK-279-CD-2003 (NCT07403968). This means that participants who responded to treatment with TAK-279 in either of the parent studies may be able to continue to benefit from the treatment in this study. The main aim of this study is to find out how safe TAK-279 is for long term use and to check if it reduces bowel inflammation and symptoms when used for a longer period of time in adults with moderately to severely active UC or CD. The participants will be treated with TAK-279 for up to 3 years (156 weeks). During the study, participants will visit their study clinic around 15 times.
Conditions
- Crohn's Disease
- Ulcerative Colitis
Interventions
ZasocitinibDrug
Zasocitinib capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)Time frame: From start of study drug administration up to Week 160 (current study)
- All Cohorts: Number of Participants With Clinically Significant Changes in Vital Sign ValuesTime frame: From start of study drug administration up to Week 160 (current study)
- All Cohorts: Number of Participants With Clinically Significant Changes in Clinical Laboratory ValuesTime frame: From start of study drug administration up to Week 160 (current study)
- Cohorts 1 and 2: Number of Participants With Clinically Significant Changes in 12-lead Electrocardiogram (ECG) ValuesTime frame: At Day 1 and Week 156 (current study)
Locations
16 sites in 8 countries. Site status is shown where the registry gives one.
Woodholme Gastroenterology Associates
Glen Burnie, Maryland · Recruiting
Tyler Research Institute, LLC
Tyler, Texas · Recruiting
Chongqing General Hospital
Chongqing, Chongqing Municipality, China · Recruiting
The First Affiliated Hospital of Sun Yat-sen University
Guangdong, Guangdong, China · Recruiting
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Renji Hospital Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China · Recruiting
Hepato-Gastroenterologie HK s.r.o.
Hradec Králové, Czechia · Recruiting
Pannonia Maganorvosi Centrum
Budapest, Hungary · Recruiting
St. Antonius Ziekenhuis
Tilburg, North Brabant, Netherlands · Recruiting
Centrum Medyczne MedykSp. z o.o. Sp. K.
Lublin, Poland · Recruiting
Twoja Przychodnia - Szczecinskie Centrum Medyczne
Szczecin, Poland · Recruiting
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, Poland · Recruiting
Gastromed Kopon Zmudzinski i Wspolnicy Sp.j.Specjalistyczne Centrum Gastrologii i Endoskopii Specj
Torun, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting
Endomed
Košice, Slovakia · Recruiting
Inje University Haeundae Paik Hospital
Haeundae, Busan Gwangyeogsi, South Korea · Recruiting
Yonsei University Wonju Severance Christian Hospital
Wŏnju, Gangwon-do, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.